The Hip Hook: Releases Unresolved Pain by Simply Laying on It

The Hip Hook: After decades of practice as a physical therapist, Christine Koth saw a pattern emerge.

Nearly everyone had a tight iliacus muscle and next to no one was aware of it. In her practice, this pattern of tightness soon became a predictable root cause of pain in the lower back, hip, tailbone, knee, and foot.

After countless successes releasing the iliacus with her hands and no effective tools on the market for people to release it themselves, Christine was compelled to create the Hip Hook, the only tool that can replicate the iliacus muscle release that only a skilled practitioner could previously provide. By simply lying upon the Hip Hook for 2 minutes per day, tension in this muscle dissolves for good.

“A tight iliacus is a missing link in recovery from back, tailbone, hip, and knee pain since it affects the alignment of the entire body. Get Hip Hooked and experience the ‘hurts so good’ release of the muscle that you didn’t know was tight.” – Christine Koth, Inventor

The Hip Hook pre-sale officially starts today with big discounts and perks here.

Christine Koth, MPT is a physical therapist who has specialized in the hip area for decades and has been aptly named the “Iliacus Queen.” She recently put the iliacus muscle on the map in her best-selling book, Tight Hip, Twisted Core – The Key to Unresolved Pain, where she uncovers the 3 major causes of a tight iliacus:

  • Too much sitting or driving
  • Overuse with activities like running, cycling, and kicking
  • Hyperflexibility, yoga, and dance

When tension in the iliacus remains unchecked, it compresses the hip and twists the core, changing the mechanics of the pelvis, spine, and hip in a way that can contribute to pain all over the body. For many, the Hip Hook is the missing link to enjoying a pain-free life. With over $30,000 sold on the first day of pre-sale, the Hip Hook is making its mark in the wellness scene. More on this here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”